AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.
Peter Wehrwein
Advertisement
Articles by Peter Wehrwein
Advertisement
Latest Updated Articles
Semaglutide Cuts Cardiovascular Risk by 20% in Adults with Obesity, CVD and Without DiabetesPublished: November 13th 2023 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
New Menopause Survey Finds Energy Loss, Poor Sleep, and Seasonal Symptoms Most Disruptive
2
The Adult Immunization Catch-Up Schedule: A Practical Guide for Primary Care
3
Undertreated Acute Pain Poses Long-Term Risks, But Prescription Opioids Still Do, Too ...
4
John Anderson, MD on How to Integrate CGM in Primary Care: "Just Do It"
5
